Background <p>Immune checkpoint inhibitors (ICI) have improved survival in various cancers, but their success in breast cancer, specifically triple-negative breast cancer, remains limited, benefiting less than 10% of patients.</p> Methods <p>We modeled ICI response in vivo to unravel the mechanisms underlying immunotherapy efficacy, identify mechanisms of resistance in non-responsive tumors, and ascertain the therapeutic benefits of different chemotherapeutic combinations with…
Monitoring systemic immune responses to checkpoint inhibition in breast cancer reveals host responses and mechanisms of resistance
Journal for ImmunoTherapy of Cancer | | Hanna, A., Sun, X., Sheng, Q., Gonzalez-Ericsson, P. I., Wescott, E. C., Taylor, B. C., Marshall, J. L., Opalenik, S. R., Toren, A. L., Sanchez, V., Fielder, C. M., Sanders, M. E., Balko, J. M.
Topics: breast-cancer, blood-cancer, immunotherapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer